Related Experiment Videos
Serum fructosamine is not a useful screening test for gestational diabetes
R Corcoy1, M J Cerqueira, J Pedreño
1Service of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|February 25, 1991
Summary
Serum fructosamine is an insensitive marker for detecting gestational diabetes in pregnant women. This study found it could only identify a small fraction of cases when used with standard glucose screening.
Area of Science:
- Clinical Biochemistry
- Reproductive Medicine
- Diabetes Research
Background:
- Gestational diabetes mellitus (GDM) poses risks to maternal and fetal health.
- Accurate and early screening for GDM is crucial for timely intervention.
- Current screening methods rely on glucose tolerance tests, which can be burdensome.
Purpose of the Study:
- To evaluate the diagnostic utility of serum fructosamine levels for detecting gestational diabetes.
- To compare the sensitivity of serum fructosamine against established GDM screening criteria.
Main Methods:
- Serum fructosamine was measured in 569 pregnant women without pre-existing diabetes.
- Abnormal fructosamine was defined as mean + 2 standard deviations (SD).
- The ability of serum fructosamine to detect GDM, diagnosed by standard screening, was analyzed.
Main Results:
- Serum fructosamine demonstrated low sensitivity as a screening parameter for GDM.
- When measured concurrently with a positive 50g glucose screening test, serum fructosamine identified only 4 out of 48 (approximately 8.3%) confirmed GDM cases.
- This suggests serum fructosamine is not a reliable standalone or adjunctive marker for GDM detection in this context.
Conclusions:
- Serum fructosamine is an insensitive biomarker for identifying gestational diabetes in pregnant women.
- Its low detection rate indicates it is not a suitable replacement or effective adjunct to current GDM screening protocols.
- Further research may be needed to explore alternative or novel biomarkers for GDM screening.